vs
Side-by-side financial comparison of Enova International, Inc. (ENVA) and ICU MEDICAL INC (ICUI). Click either name above to swap in a different company.
Enova International, Inc. is the larger business by last-quarter revenue ($875.1M vs $540.7M, roughly 1.6× ICU MEDICAL INC). Enova International, Inc. runs the higher net margin — 10.4% vs -2.9%, a 13.3% gap on every dollar of revenue. On growth, Enova International, Inc. posted the faster year-over-year revenue change (17.4% vs -14.1%). Over the past eight quarters, Enova International, Inc.'s revenue compounded faster (18.0% CAGR vs -2.3%).
Enova International, Inc. is a global fintech firm providing online financial solutions including short-term consumer loans and small business financing. It operates mainly across North America, South America and Europe, using advanced data analytics to assess creditworthiness and deliver tailored products to underserved borrower segments.
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
ENVA vs ICUI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $875.1M | $540.7M |
| Net Profit | $91.1M | $-15.7M |
| Gross Margin | — | 37.5% |
| Operating Margin | 23.7% | 1.0% |
| Net Margin | 10.4% | -2.9% |
| Revenue YoY | 17.4% | -14.1% |
| Net Profit YoY | 24.9% | 34.0% |
| EPS (diluted) | $3.46 | $-0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $875.1M | — | ||
| Q4 25 | $839.4M | $540.7M | ||
| Q3 25 | $802.7M | $537.0M | ||
| Q2 25 | $764.0M | $548.9M | ||
| Q1 25 | $745.5M | $604.7M | ||
| Q4 24 | $729.6M | $629.8M | ||
| Q3 24 | $689.9M | $589.1M | ||
| Q2 24 | $628.4M | $596.5M |
| Q1 26 | $91.1M | — | ||
| Q4 25 | $79.0M | $-15.7M | ||
| Q3 25 | $80.3M | $-3.4M | ||
| Q2 25 | $76.1M | $35.3M | ||
| Q1 25 | $72.9M | $-15.5M | ||
| Q4 24 | $63.7M | $-23.8M | ||
| Q3 24 | $43.4M | $-33.0M | ||
| Q2 24 | $53.9M | $-21.4M |
| Q1 26 | — | — | ||
| Q4 25 | 59.8% | 37.5% | ||
| Q3 25 | 57.4% | 37.4% | ||
| Q2 25 | 57.8% | 37.9% | ||
| Q1 25 | 57.2% | 34.7% | ||
| Q4 24 | 56.6% | 36.1% | ||
| Q3 24 | 58.0% | 34.8% | ||
| Q2 24 | 58.9% | 34.8% |
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.2% | 1.0% | ||
| Q3 25 | 24.5% | 2.6% | ||
| Q2 25 | 24.1% | 1.9% | ||
| Q1 25 | 23.1% | 2.1% | ||
| Q4 24 | 21.3% | 6.0% | ||
| Q3 24 | 22.3% | 1.4% | ||
| Q2 24 | 23.1% | 1.3% |
| Q1 26 | 10.4% | — | ||
| Q4 25 | 9.4% | -2.9% | ||
| Q3 25 | 10.0% | -0.6% | ||
| Q2 25 | 10.0% | 6.4% | ||
| Q1 25 | 9.8% | -2.6% | ||
| Q4 24 | 8.7% | -3.8% | ||
| Q3 24 | 6.3% | -5.6% | ||
| Q2 24 | 8.6% | -3.6% |
| Q1 26 | $3.46 | — | ||
| Q4 25 | $2.94 | $-0.63 | ||
| Q3 25 | $3.03 | $-0.14 | ||
| Q2 25 | $2.86 | $1.43 | ||
| Q1 25 | $2.69 | $-0.63 | ||
| Q4 24 | $2.29 | $-0.97 | ||
| Q3 24 | $1.57 | $-1.35 | ||
| Q2 24 | $1.93 | $-0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.1M | — |
| Total DebtLower is stronger | $4.8B | — |
| Stockholders' EquityBook value | — | $2.1B |
| Total Assets | $6.9B | $4.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $96.1M | — | ||
| Q4 25 | $71.7M | — | ||
| Q3 25 | $53.6M | — | ||
| Q2 25 | $55.6M | — | ||
| Q1 25 | $55.5M | — | ||
| Q4 24 | $73.9M | $308.6M | ||
| Q3 24 | $67.5M | $312.5M | ||
| Q2 24 | $60.1M | $302.6M |
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $3.8B | — | ||
| Q4 24 | $3.6B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $3.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.2B | $2.0B | ||
| Q3 24 | $1.2B | $2.0B | ||
| Q2 24 | $1.1B | $2.0B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.5B | $4.1B | ||
| Q3 25 | $6.0B | $4.1B | ||
| Q2 25 | $5.7B | $4.1B | ||
| Q1 25 | $5.5B | $4.2B | ||
| Q4 24 | $5.3B | $4.2B | ||
| Q3 24 | $5.0B | $4.3B | ||
| Q2 24 | $4.8B | $4.3B |
| Q1 26 | — | — | ||
| Q4 25 | 3.37× | — | ||
| Q3 25 | 3.20× | — | ||
| Q2 25 | 3.23× | — | ||
| Q1 25 | 3.14× | — | ||
| Q4 24 | 2.98× | — | ||
| Q3 24 | 2.79× | — | ||
| Q2 24 | 2.78× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.6M |
| Free Cash FlowOCF − Capex | — | $36.0M |
| FCF MarginFCF / Revenue | — | 6.6% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $91.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $498.8M | $60.6M | ||
| Q3 25 | $481.8M | $56.7M | ||
| Q2 25 | $447.4M | $11.2M | ||
| Q1 25 | $391.1M | $51.3M | ||
| Q4 24 | $430.5M | $40.2M | ||
| Q3 24 | $398.6M | $36.1M | ||
| Q2 24 | $360.9M | $82.0M |
| Q1 26 | — | — | ||
| Q4 25 | $487.1M | $36.0M | ||
| Q3 25 | $470.5M | $27.6M | ||
| Q2 25 | $436.1M | $-8.5M | ||
| Q1 25 | $378.3M | $36.7M | ||
| Q4 24 | $420.3M | $16.1M | ||
| Q3 24 | $387.6M | $16.2M | ||
| Q2 24 | $349.9M | $62.5M |
| Q1 26 | — | — | ||
| Q4 25 | 58.0% | 6.6% | ||
| Q3 25 | 58.6% | 5.1% | ||
| Q2 25 | 57.1% | -1.5% | ||
| Q1 25 | 50.7% | 6.1% | ||
| Q4 24 | 57.6% | 2.6% | ||
| Q3 24 | 56.2% | 2.7% | ||
| Q2 24 | 55.7% | 10.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 4.6% | ||
| Q3 25 | 1.4% | 5.4% | ||
| Q2 25 | 1.5% | 3.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 1.4% | 3.8% | ||
| Q3 24 | 1.6% | 3.4% | ||
| Q2 24 | 1.8% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 6.32× | — | ||
| Q3 25 | 6.00× | — | ||
| Q2 25 | 5.87× | 0.32× | ||
| Q1 25 | 5.36× | — | ||
| Q4 24 | 6.76× | — | ||
| Q3 24 | 9.18× | — | ||
| Q2 24 | 6.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENVA
Segment breakdown not available.
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
